Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

19-<i>nor</i>-Clerodane Diterpenoid Dimers from <i>Croton euryphyllus</i> and Their NLRP3 Inflammasome Inhibitory Activity.

Organic letters·2026
Same author

Biological Evaluation of Esters of 4-Carboxylate-1,2,3-triazine and Analogs as New Potential Anti-<i>Mycobacterium tuberculosis</i> Agents.

Molecules (Basel, Switzerland)·2026
Same author

Structural Significance and Reference Value of High-Precision Coupling Constants and Raw Data Sharing.

Analytical chemistry·2026
Same author

Phainanones A-D, Four Aromatic Diterpenoids with Anti-HIV Activity from <i>Phyllanthus hainanensis</i>.

Journal of natural products·2026
Same author

There is No Caffeine in Damiana-Dismantling Filter Bubbles and Echo Chambers in Scientific Referencing.

Planta medica·2026
Same author

Multilevel Residual Complexity Analysis Reveals Origin of Nanomolar Antiviral Bioactives of "Isoquercitrin".

Journal of natural products·2026

Related Experiment Video

Updated: May 20, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K

Structure-Based Analysis of Semisynthetic Anti-TB Rufomycin Analogues.

Bin Zhou, Gauri Shetye, Larry L Klein

  • 1Myongji Bioefficacy Research Center, Myongji University, Myongji-Ro 116, Yongin, Gyeonggi-Do 17058, Republic of Korea.

Journal of Natural Products
|March 24, 2025
PubMed
Summary
This summary is machine-generated.

Researchers designed new rufomycin analogues to combat tuberculosis (TB). Several analogues showed improved potency against Mycobacterium tuberculosis (Mtb), with two compounds exhibiting significantly enhanced activity.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.4K

Related Experiment Videos

Last Updated: May 20, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.5K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.4K

Area of Science:

  • Medicinal Chemistry
  • Structural Biology
  • Microbiology

Background:

  • Rufomycins are natural products with antituberculosis activity.
  • Understanding the interaction between rufomycins and their target, ClpC1, is crucial for drug development.

Purpose of the Study:

  • To design and synthesize novel rufomycin analogues using structural information.
  • To evaluate the antituberculosis activity and structure-activity relationships (SAR) of these analogues.
  • To elucidate the binding interactions with ClpC1.

Main Methods:

  • Cocrystallization of rufomycin analogues with ClpC1-NTD.
  • Semisynthesis of 30 rufomycin analogues.
  • In vitro evaluation of minimum inhibitory concentrations (MICs) against Mycobacterium tuberculosis (Mtb).
  • X-ray crystallography to determine cocrystal structures.
  • Analysis of protein-ligand interactions.

Main Results:

  • 14 out of 30 analogues showed improved or similar MICs compared to natural rufomycins.
  • Compounds 5 and 27 demonstrated 10-fold enhanced potency against Mtb (MICs of 1.9 and 1.4 nM, respectively).
  • A new crystal structure of analogue 11 revealed conformational changes and confirmed the importance of specific regions for activity.
  • Differential interactions with the ClpC1 N-terminal tail explained varying modes of action.

Conclusions:

  • The study successfully generated potent rufomycin analogues with enhanced antituberculosis activity.
  • Structural insights guided the optimization of rufomycin analogues, informing future SAR studies.
  • Understanding the molecular interactions provides a basis for developing new ClpC1-targeting antibiotics.